Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacogenetics in solid organ transplantation: present knowledge and future perspectives.

Dany Anglicheau1, Christophe Legendre, Eric Thervet

  • 1Service de Néphrologie et de Transplantation Rénale, Hôpital Saint Louis, Paris, France.

Transplantation
|August 19, 2004
PubMed
Summary

Pharmacogenetics uses genetic variations to personalize drug therapy. Understanding genetic influences on drug metabolism, like thiopurine methyltransferase (TPMT) and cytochrome P450 genes, improves patient safety and treatment efficacy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The risk of venous thromboembolism in kidney transplant recipients is enhanced following a cytomegalovirus infection.

Frontiers in immunology·2026
Same author

Qualified prediction system for allograft failure in real world settings: extended validation study.

BMJ medicine·2026
Same author

Corrigendum to "Molecular diagnosis of kidney allograft rejection based on the Banff Human Organ Transplant gene panel: A multicenter international study" [American Journal of Transplantation 25 (2025) 1631-1642].

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

A Prediction Model for Risk of Death in Kidney Transplant Recipients.

JAMA network open·2026
Same author

Impaired thymic function is independently associated with an increased risk of posttransplant infections in kidney recipients.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

Genetic screening in kidney transplant candidates.

Clinical kidney journal·2026

Area of Science:

  • Pharmacogenetics
  • Genomics
  • Drug Metabolism

Background:

  • Individual responses to drugs vary due to inherited genetic differences.
  • Genetic polymorphisms significantly impact the pharmacokinetics and pharmacodynamics of immunosuppressive drugs.
  • Thiopurine methyltransferase (TPMT) is a key enzyme in azathioprine metabolism, with low activity leading to myelosuppression.

Purpose of the Study:

  • To explore the role of genetic polymorphisms in drug response variability.
  • To highlight the clinical application of pharmacogenetics in optimizing drug therapy.
  • To identify genetic markers for predicting drug efficacy and toxicity.

Main Methods:

  • Investigated genetic polymorphisms in thiopurine methyltransferase (TPMT), cytochrome P450 (CYP450) enzymes (3A5, 3A4), and multidrug resistance-1 (MDR1) gene.

Related Experiment Videos

  • Utilized TPMT activity determination and DNA-based tests for clinical assessment.
  • Examined the association between gene polymorphisms and drug dosage requirements.

    • Main Results:

    • Low TPMT activity, inherited codominantly, increases the risk of myelosuppression from azathioprine.
    • Polymorphisms in CYP450 3A5, 3A4, and MDR1 genes correlate with the daily dose of tacrolimus needed for therapeutic blood levels.
    • Haplotype analysis and combined gene associations show potential for improved prediction of drug response.

    Conclusions:

    • Pharmacogenetics enables personalized medicine by tailoring drug selection and dosage based on individual genetic profiles.
    • Genetic testing for TPMT and CYP450/MDR1 related polymorphisms is crucial for safe and effective immunosuppressive therapy.
    • Advancements in genotyping technology will facilitate broader application of pharmacogenetics, though prospective clinical validation remains essential.